Lexicon Pharmaceuticals | LXRX - Cash And Equivalent

Stock Price
1.84
Daily Change
-0.03 -1.60%
Monthly
12.20%
Yearly
220.00%
Q2 Forecast
1.83

Lexicon Pharmaceuticals reported $21.36M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Akebia Therapeutics USD 184.84M 18.4M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Illumina USD 1.42B 368M Dec/2025
Insmed USD 510.44M 175.68M Dec/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Lexicon Pharmaceuticals USD 21.36M 41.52M Jun/2025
MacroGenics USD 57.22M 22.91M Dec/2025
MannKind USD 74.88M 52.51M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
United Therapeutics USD 1.56B 217M Dec/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025